Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial.

Journal: Clinical nutrition (Edinburgh, Scotland)
PMID: 29275919

Abstract

BACKGROUND & AIMS: Melatonin may benefit diabetic people with coronary heart disease (CHD) through its beneficial effects on biomarkers of oxidative stress and cardio-metabolic risk. This investigation evaluated the effects of melatonin administration on metabolic status in diabetic patients with CHD.

Authors

  • Fariba Raygan
    Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran.
  • Vahidreza Ostadmohammadi
    Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran; Student Research Committee, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran.
  • Fereshteh Bahmani
    Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
  • Russel J Reiter
    Department of Cellular and Structural Biology, University of Texas Health Science, Center, San Antonio, TX, USA.
  • Zatollah Asemi
    Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: asemi_r@yahoo.com.

Keywords

External Resources

Popular Topics
Recent Journals